Efficacy and Safety of Belatacept Treatment in Renal Allograft Recipients at High Cardiovascular Risk—A Single Center Experience

Belatacept is an attractive option for immunosuppression after renal transplantation. Renal allograft function is superior when compared to calcineurin inhibitor (CNI) based therapy in “de novo” treated patients and it has also been proposed that individuals at high cardiovascular (CV) risk may bene...

Descripción completa

Detalles Bibliográficos
Autores principales: Neuwirt, Hannes, Leitner-Lechner, Irmgard, Kerschbaum, Julia, Ertl, Michael, Pöggsteiner, Florian, Pölt, Nicolas, Mätzler, Julius, Sprenger-Mähr, Hannelore, Rudnicki, Michael, Schratzberger, Peter, Eder, Iris E., Mayer, Gert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723198/
https://www.ncbi.nlm.nih.gov/pubmed/31382583
http://dx.doi.org/10.3390/jcm8081164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723198/
https://www.ncbi.nlm.nih.gov/pubmed/31382583
http://dx.doi.org/10.3390/jcm8081164

Ejemplares similares